Skip to main content

Brexucabtagene autoleucel Disease Interactions

There is 1 disease interaction with brexucabtagene autoleucel.

Major

Brexucabtagene autoleucel (applies to brexucabtagene autoleucel) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Brexucabtagene autoleucel has caused severe or life-threatening infections, including hepatitis B reactivation and fatal opportunistic infections in immunosuppressed patients. Screening for hepatitis B and C virus, and for human immunodeficiency virus (HIV) in accordance with clinical guidelines should be performed before collection of cells for manufacturing. Monitor patients for signs and symptoms of infection before and after infusion, administer prophylactic antimicrobials as needed, and treat promptly and appropriately any infection.

References

  1. (2020) "Product Information. Tecartus (brexucabtagene autoleucel)." Kite Pharma, Inc.

Brexucabtagene autoleucel drug interactions

There are 198 drug interactions with brexucabtagene autoleucel.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer